Salubris Biotherapeutics, Inc., Gaithersburg, MD-based, clinical stage biotechnology company, was awarded $32m in funding. China’s Shenzhen Salubris Pharmaceuticals Co. made the investment.
The company intends to use the funds to used to advance the current pipeline, including continuation of an ongoing Phase 1b clinical trial and initiation of two additional Phase 1b clinical trials in 2022, and to further expand the pipeline through R&D.
Sam Murphy, chief executive officer, is leading SalubrisBio’s drug discovery and research platform. He has been instrumental in addressing significant unmet medical need in the areas of cancer, heart disease, and neurodegenerative disorders. There are multiple assets in preclinical/clinical development, as well as additional programs at discovery stage. The company’s lead asset, JK07, is an antibody-based NRG-1 fusion protein currently in Phase 1 trials to assess safety and tolerability and to explore activity in subjects with heart failure with reduced ejection fraction [HFrEF]. JK07 is the world’s first bi-specific antibody to be used in clinical trials for a cardiovascular indication.